title: [Metastatic tumors of the vulva: a report of 78 cases].
abstract: OBJECTIVE
  To study the clinical characteristics, diagnosis and reasonable therapy for metastatic tumors of vulva.
  
  
  METHODS
  Seventy eight cases with metastatic tumors of the vulva were retrospectively reviewed. The cervical carcinoma was the most frequent primary site (61 cases), followed by the urethra (5 cases), vagina (4 cases), endometrium (3 cases), breast (2 cases), ovary (1 cases), rectum carcinoma (1 cases) and malignant lymphoma (1 cases).
  
  
  RESULTS
  The median age of this series was 55. 75.6%(59/78) of the patients subsequently developed vulvar metastasis from 15 days to 18 years after the primary tumors diagnosed, the median interval was 2.5 years. 61.5%(48/78) patients combined with primary site recurrence or other place metastasis, primary site recurrence were 35.4%, inguinal lymph node metastasis 45.8%, supraclavicular lymph node metastasis 8.3%, pelvic metastasis 8.3% and hematogenous metastasis 12.5% (liver, lung, skeleton). Radiotherapy was the main therapeutic approch, some cases combined with surgery and/or chemotherapy. The overall 1 year, 3 years and 5 years survival rates after vulvar metastatic occurrence were 65.4%, 29.5% and 16.7% respectively.
  
  
  CONCLUSIONS
  The prognosis of the vulva metastatic tumors was poor. Radiotherapy combine with surgery and/or chemotherapy can improve the survival.
authors.affiliation: Department of Gynecology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021.
authors.forename: H
authors.initials: H
authors.lastname: Chao
authors.forename: J
authors.initials: J
authors.lastname: Sun
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000556:secondary* / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000628:therapy; D014846:Vulvar Neoplasms / Q000556:secondary* / Q000628:therapy